Tumor antigens for cancer immunotherapy: therapeutic potential of xenogeneic DNA vaccines

por Srinivasan, Roopa, Wolchok, Jedd D
Publicado 2004

Immunotherapy and the belly of the beast

por Merghoub, Taha, Wolchok, Jedd D.
Publicado 2014

Potentiation of immunomodulatory antibody therapy with oncolytic viruses for treatment of cancer

por Zamarin, Dmitriy, Wolchok, Jedd D
Publicado 2014

Shared cancer neoantigens: Making private matters public

por Klebanoff, Christopher A., Wolchok, Jedd D.
Publicado 2018

The many faces of the anti-COVID immune response

por Vardhana, Santosha A., Wolchok, Jedd D.
Publicado 2020

Myeloid-derived suppressor cells and the efficacy of CD8(+) T-cell immunotherapy

por Lesokhin, Alexander M., Merghoub, Taha, Wolchok, Jedd D.
Publicado 2013

Hiding the road signs that lead to tumor immunity

por Schaer, David A., Lesokhin, Alexander M., Wolchok, Jedd D.
Publicado 2011

Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy

por Schaer, David A, Hirschhorn-Cymerman, Daniel, Wolchok, Jedd D
Publicado 2014

CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic

por Callahan, Margaret K., Postow, Michael A., Wolchok, Jedd D.
Publicado 2015

The future of cancer immunotherapy: microenvironment-targeting combinations

por Murciano-Goroff, Yonina R., Warner, Allison Betof, Wolchok, Jedd D.
Publicado 2020

Ipilimumab in patients with melanoma and autoimmune disease

por Kyi, Chrisann, Carvajal, Richard D, Wolchok, Jedd D, Postow, Michael A
Publicado 2014

The delicate balance of melanoma immunotherapy

por Gyorki, David E, Callahan, Margaret, Wolchok, Jedd D, Ariyan, Charlotte E
Publicado 2013

Targeting myeloid-derived suppressor cells with colony stimulating factor-1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2,3-dioxygenase-expressi...

por Holmgaard, Rikke B., Zamarin, Dmitriy, Lesokhin, Alexander, Merghoub, Taha, Wolchok, Jedd D.
Publicado 2016

Expression of indoleamine 2.3-dioxygenase by tumors induces local and systemic immunosuppressive effects in a murine melanoma model

por Holmgaard, Rikke B, Zamarin, Dmitriy, Munn, David H, Merghoub, Taha, Wolchok, Jedd D
Publicado 2014

Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4

por Holmgaard, Rikke B., Zamarin, Dmitriy, Munn, David H., Wolchok, Jedd D., Allison, James P.
Publicado 2013

Indoleamine 2,3-dioxygenase is a critical resistance mechanism in anti-tumor T cell immunotherapy targeting CTLA-4

por Holmgaard, Rikke B, Zamarin, Dmitriy, Munn, David H, Wolchok, Jedd D, Allison, James P
Publicado 2013

Opportunistic infections in patients treated with immunotherapy for cancer

por Kyi, Chrisann, Hellmann, Matthew D, Wolchok, Jedd D, Chapman, Paul B, Postow, Michael A
Publicado 2014

Potentiation of immunomodulatory antibodies with oncolytic viruses for therapy of poorly-immunogenic tumors

por Zamarin, Dmitriy, Holmgaard, Rikke B, Plitt, Tamar, Allison, James, Merghoub, Taha, Wolchok, Jedd D
Publicado 2014

Progressive choroidal thinning (leptochoroid) and fundus depigmentation associated with checkpoint inhibitors

por Canestraro, Julia, Jaben, Korey A., Wolchok, Jedd D., Abramson, David H., Francis, Jasmine H.
Publicado 2020

Blockade of surface bound TGF-β abrogates Treg suppression of effector T cell function within the tumor microenvironment

por Budhu, Sadna, Schaer, David, Li, Yongbiao, Houghton, Alan, Silverstein, Samuel, Merghoub, Taha, Wolchok, Jedd D
Publicado 2014